Abstract
Purpose:
To evaluate the efficacy of focal verteporfin photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (CSC)
Methods:
Fifty-two eyes of 52 patients with chronic CSC who had received verteporfin PDT were enrolled. The laser spot size of 26 eyes to cover only the localized hyperfluorescent area on indocyanine green angiography (ICGA) was classified as focal PDT. The PDT spot size of other 26 eyes to cover total area including leaking point and detachment of retinal pigment epithelium was conventional PDT. The foveal thickness and subfoveal choroidal thickness was measured using Heidelberg Spectralis OCT before PDT at baseline and months 1, 3, 6, 12.
Results:
The mean spot size for PDT was 1995.00 ㎛ in focal group and 2995.00 ㎛ in conventional group. Foveal thickness was steadily decreased in both groups. The mean baseline subfoveal choroidal thickness was 334.95 ㎛, 348.35 ㎛ in each group and there were no significant differences between two groups (p=0.602). The mean subfoveal choroidal thickness decreased significantly to 304.20 ㎛ at 1 month, 284.85 ㎛ at 3 month, 271.60 ㎛ at 6 month and 265.95 ㎛ at 12 month in focal group (p<0.001, p<0.001, p<0.001 and p<0.001, respectively compared with baseline). In conventional group, it decreased significantly to 318.75 ㎛, 300.00 ㎛, 284.00 ㎛, 272.00 ㎛ at 1, 3, 6, 12 month (p<0.001, p<0.001, p<0.001 and p<0.001, respectively compared with baseline). There were no significant differences between two groups with regard to subfoveal choroidal thickness according to PDT spot size at 1, 3, 6, 12 month (p=0.602, p=0.565, p=0.659 and p=0.640, respectively).
Conclusions:
Focal verteporfin PDT for CSC significantly resulted in decreasing subretinal fluid and sufoveal choroidal thickness as well as conventional PDT.